ArticleInternational journal of oncology2017
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
Chinami Masuda et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
52 papers cite it
this paperpooled ittrialcites it